Literature DB >> 34213671

Comparative effectiveness of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease.

Konstantinos Gkiouras1, Maria G Grammatikopoulou1,2, Theodora Simopoulou1, Zoe Daniil3, Dimitrios P Bogdanos4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 34213671     DOI： 10.1007/s10067-021-05845-x

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN： 0770-3198            Impact factor:   2.980


× No keyword cloud information.
  4 in total

1.  What makes placebo-controlled trials unethical?

Authors:  Franklin G Miller; Howard Brody
Journal:  Am J Bioeth       Date:  2002       Impact factor: 11.229

2.  Efficacy of mycophenolate mofetil versus cyclophosphamide in systemic sclerosis-related interstitial lung disease: a systematic review and meta-analysis.

Authors:  Xinyu Ma; Rui Tang; Mei Luo; Zhuotong Zeng; Yaqian Shi; Bingsi Tang; Rong Xiao
Journal:  Clin Rheumatol       Date:  2021-06-02       Impact factor: 2.980

3.  Using meta-analyses for comparative effectiveness research.

Authors:  Vicki S Conn; Todd M Ruppar; Lorraine J Phillips; Jo-Ana D Chase
Journal:  Nurs Outlook       Date:  2012 Jul-Aug       Impact factor: 3.250

4.  Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and II.

Authors:  Elizabeth R Volkmann; Donald P Tashkin; Ning Li; Michael D Roth; Dinesh Khanna; Anna-Maria Hoffmann-Vold; Grace Kim; Jonathan Goldin; Philip J Clements; Daniel E Furst; Robert M Elashoff
Journal:  Arthritis Rheumatol       Date:  2017-05-23       Impact factor: 15.483
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.